p 5

BMS-P5 is a specific and orally active Peptidylarginine Deiminase 4 (PAD4) inhibitor.

BMS-P5 free base is a specific and orally active peptidylarginine deiminase 4 (PAD4) inhibitor that blocks the formation of Neutrophil Extracellular Traps and delays the progression of multiple myeloma. Administration of BMS-P5 to multiple myeloma-bearing mice delays symptom onset and disease progression. Targeting PAD4 may be beneficial for treating multiple myeloma.

p5 Ligand for Dnak and DnaJ is a nonapeptide corresponding to the primary binding sites of the 23-residue mitochondrial aspartate aminotransferase presequence. p5 ligand is a high-affinity ligand for Dnak and DnaJ.

p5 Ligand for Dnak and DnaJ acetate is a nonapeptide. It is a high-affinity ligand for DnaK (E. coli Hsp70) and DnaJ (E. coli Hsp40).

MTvkPABC-P5d TFA, a TLR7 agonist, functions as an immune stimulant. It is applicable in the synthesis of immune-stimulating antibody conjugates (ISAC).

P5(PEG12)-VC-PAB-Exatecan (LP3) is an integral part of a drug-linker conjugate for ADC, formed by linking P5(PEG24)-VC-PAB with the DNA topoisomerase I inhibitor, Exatecan. It is utilized in the preparation of antibody-drug conjugates (ADC) and employed in tumor research.

Aseanostatin P5 inhibits myeloperoxidase (MPO) release from human polymorphonuclear leukocytes.

MTvkPABC-P5d, functioning as a TLR7 agonist, serves as an immune stimulant and is utilized in the synthesis of immune-stimulating antibody conjugates (ISACs) [1].

Pardaxin P5, an antimicrobial peptide, inhibits Escherichia coli at a minimum inhibitory concentration (MIC) of 13 μM [1].

P5(PEG24)-VC-PAB-exatecan, a camptothecin-based linker-payload platform, utilizes the highly potent derivative exatecan. This compound features linker-payload structures and is primarily employed in the research of tumor [1].

Ethanol, 2,2'-((p-(5-phenylpentyloxy)phenyl)imino)di- is a bioactive chemical.

Ethylenediamine, N,N-diethyl-N'-(p-(5-phenoxypentyloxy)phenyl)- is a bioactive chemical.

[Glp5] Substance P (5-11), an octapeptide, is a key fragment of substance P in the rat central nervous system (CNS) and plays a localized role in modulating dopamine release in the rat striatum [1].

[Glp5,(Me)Phe8,Sar9] Substance P (5-11) (DiMe-C7) is an analogue of Substance P that acts on the neurokinin 1 receptor (NK1R) in rat brain, similarly to Substance P but with a significantly extended duration of action. This compound selectively enhances dopamine metabolism within the mesencephalon and midbrain cortex, increases motor activity, and facilitates the resumption of addictive agent-seeking behavior in rats [1] [2] [3].

[Glp5,Sar9] Substance P (5-11) is an analogue of Substance P [1].

P5SA-2 is a selective allosteric activator of PPP5C, functioning by modulating the structure of the PPP5C phosphatase domain. At a concentration of 100 μM, it can enhance PPP5C activity by 3.2-fold, with an apparent affinity constant of 7.8 μM. P5SA-2 is applicable in research related to cancer and Alzheimer's disease.

D-myo-Inositol-1,3,4,5,6-pentaphosphate (ammonium salt) [Ins(1,3,4,5,6)P5 (ammonium salt)] is an isomer of inositol phosphate that functions as a small, soluble second messenger in cellular signaling. It can bind to the PH domain of Grp1 with a dissociation constant (Kd) of 590 nM. This compound inhibits the phosphorylation and kinase activity of Akt/PKB, leading to apoptosis in ovarian, lung, and breast cancer cells. Additionally, it exhibits anti-angiogenic activity in vitro, blocking capillary formation by HUVECs, and demonstrates antitumor effects in cancer xenograft models in nude mice.

D-myo-Inositol-1,2,4,5,6-pentaphosphate (Ins(1,2,4,5,6)P5) sodium salt is one of several inositol polyphosphate isomers involved in signal transduction. In human Jurkat T lymphocytes, Ins(1,2,4,5,6)P5 (sodium salt) is phosphorylated by 1/3 kinase to form InsP6. This compound plays a role in calcium signaling pathways.

D-myo-Inositol-1,2,3,5-tetraphosphate (Ins(1,2,3,5,6)-P5) tetrasodium is one of the inositol phosphate isomers that acts as a soluble second messenger in cellular calcium signaling.

FAUC 213 is a selective full antagonist of the dopamine D4 receptor.

S1P5 Receptor Agonist-1 (example 6) is a highly potent and selective agonist for the S1P5 receptor, exhibiting an EC50 value of 20 nM.

P53 Activator 5 is a potent activator of p53, exhibiting a SC150 value of less than 0.05 mM. It effectively binds to mutant p53, restoring its DNA-binding capability. Additionally, P53 Activator 5 demonstrates significant anti-tumor activity.

p53-MDM2-IN-5 (compound 5a), a robust p53-MDM2 inhibitor, effectively induces apoptosis, autophagy, and DNA damage. It also causes cell cycle arrest at the S and G2/M phases and demonstrates anti-tumor activity.

Exendin-P5, a selective agonist for GLP-1R, enhances the potency of G protein-mediated signaling through rapid activation of G proteins via transient interactions with the GLP-1R transmembrane domain. This action accelerates cAMP production, pointing to Exendin-P5's potential use in researching metabolic diseases.